Concepedia
Statistics
Publications
14
Citations
7.4K
H-Index
13
Active since
1994
Affiliations
Eli Lilly (United States)(Current)
Vanderbilt University
Université Paris Cité
Iowa State University
Cliniques Universitaires Saint-Luc
Jeffrey D. Helterbrand is an author at Eli Lilly (United States) specializing in sepsis, medicine, and sepsis management.
Publications per year
1994–2011
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Gordon R. Bernard, Jean‐Louis Vincent, Pierre‐François Laterre et al. · New England Journal of Medicine · 2001 · 6.1K citations · Full text
Medicine, Pharmacology, Pharmacotherapy +13
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus et al. · Critical Care Medicine · 2003 · 283 citations
Medicine, Pharmacology, Pharmacotherapy +17
Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis
S. Betty Yan, Jeffrey D. Helterbrand, Daniel Hartman et al. · CHEST Journal · 2001 · 258 citations
Veterinary Medicine, Immunology, Infectious Diseases +16
The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)
GR Bernard, SP LaRosa, Pierre‐François Laterre et al. · Digital Access to Libraries · 2001 · 213 citations
Veterinary Medicine, Immunology, Pharmacology +7
Design and methods of the Raloxifene Use for The Heart (RUTH) study
Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger et al. · The American Journal of Cardiology · 2001 · 166 citations
Medicine, Cardiology, Pharmacology +5
1–5 of 14